Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells
Cancer Cell International, Volume 7, Article 5, Year 2007
Notification
URL copied to clipboard!
Description
Background: The pharmacologic modulatory effects of the antibiotic, tunicamycin (TM), on multidrug-resistant human UWOV2 ovarian cancer cells are reported. The UWOV2 cell line was derived from a cystadenocarcinoma in a patient refractory to combination chemotherapy with actinomycin D, vincristine (VCR), cis-diaminedichloroplatinum (II) (CDDP) and doxorubicin (DXR). In an attempt to explain drug resistance in this cell line, we examined the effects of TM on their sensitivity to various anticancer drugs, the uptake, efflux and retention of [3H]VCR, and their ability to bind [14C]DXR and [3H]azidopine (AZD), a photoaffinity label of the multidrug transporter, P-glycoprotein (Pgp). Results: TM effectively decreased the EC50 for DXR, EXR, VCR and CDDP, thus enhancing their cytotoxicity. The antibiotic also prolonged the intracellular retention time of [3H]VCR and increased the binding of both [14C]DXR and [3H]AZD to the cells. Conclusion: It is concluded that the pharmacomodulatory effects of TM in these cells are mediated by global inhibition of protein and glycoprotein synthesis and synergistic interaction with antineoplastic drugs. The ability of TM to enhance the sensitivity of drug resistant tumour cells may have impact on the design and optimization of novel resistance modifiers to improve the efficacy of combination treatment of intractable neoplasms. © 2007 Hiss et al; licensee BioMed Central Ltd.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC1865531/bin/1475-2867-7-5-S1.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC1865531/bin/1475-2867-7-5-S2.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC1865531/bin/1475-2867-7-5-S3.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC1865531/bin/1475-2867-7-5-S4.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC1865531/bin/1475-2867-7-5-S5.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC1865531/bin/1475-2867-7-5-S6.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC1865531/bin/1475-2867-7-5-S7.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC1865531/bin/1475-2867-7-5-S8.doc
Authors & Co-Authors
Hiss, D. C.
South Africa, Cape Town
University of Cape Town
South Africa, Bellville
University of the Western Cape
Gabriels, Gary A.
South Africa, Cape Town
University of Cape Town
Folb, Peter I.
South Africa, Cape Town
University of Cape Town
South Africa, Tygerberg
South African Medical Research Council
Statistics
Citations: 183
Authors: 3
Affiliations: 3
Identifiers
Doi:
10.1186/1475-2867-7-5
e-ISSN:
14752867
Research Areas
Cancer
Health System And Policy